European Journal of Clinical Pharmacology · Nov 18, 2026
Correspondence: Reply to "Heterogeneity in dosages and treatment conditions forms a blurred picture of the results"
By Hussain M, Hassan M, Sohaib A et al.
Jumani et al. raised concerns about our systematic review and meta-analysis of zilebesiran in adults with hypertension, concerning dose heterogeneity, differences in trial conditions, and statistical methods. In this reply, we clarify that the primary analysis was pre-specified to include one comparison per trial, using the 300 or 400 mg dose at 6 months. The pooled blood pressure estimates therefore did not combine different doses. We agree that the dose subgroup analyses were underpowered and exploratory, and we did not conclude that doses are equivalent. We also acknowledge that trial populations, background antihypertensive therapy, and follow-up differed, and that the "mild to moderate" label should be interpreted cautiously. With only two trials per efficacy outcome, between-study variance cannot be estimated reliably and prediction intervals cannot be calculated. The pooled estimates should therefore be regarded as preliminary. These points support our call for larger, long-term trials with active comparators.
doi.org/10.1007/s00228-026-04222-4PubMed 43049923Interventions